Baylor College of Medicine: Researchers Engineer Better Way to Target Leukemia Cells
April 07, 2020
April 07, 2020
HOUSTON, Texas, April 7 -- The Baylor College of Medicine issued the following news release:
Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer. While most children respond well to chemotherapy, some experience resistant or relapsed disease. Building on an immunotherapy treatment called CAR T cell therapy, researchers at Baylor College of Medicine, working with colleagues from multiple institutions, were able to engineer a new fighter T cell that more effectively . . .
Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer. While most children respond well to chemotherapy, some experience resistant or relapsed disease. Building on an immunotherapy treatment called CAR T cell therapy, researchers at Baylor College of Medicine, working with colleagues from multiple institutions, were able to engineer a new fighter T cell that more effectively . . .